

Europe Acute Myeloid Leukemia (AML) Therapeutic Market Report 2016

<https://marketpublishers.com/r/E99A29625B1EN.html>

Date: November 2016

Pages: 114

Price: US\$ 3,900.00 (Single User License)

ID: E99A29625B1EN

Abstracts

Notes:

Sales, means the sales volume of Acute Myeloid Leukemia (AML) Therapeutic

Revenue, means the sales value of Acute Myeloid Leukemia (AML) Therapeutic

This report studies sales (consumption) of Acute Myeloid Leukemia (AML) Therapeutic in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering

Ambit Biosciences Inc. (US)

Aprea AB (Sweden)

Astellas Pharma Inc. (Japan)

Astex Pharmaceuticals, Inc. (US)

Bio-Path Holdings, Inc. (US)

BioSante Pharmaceuticals, Inc. (US)

Celator Pharmaceuticals, Inc. (US)

Celgene Corp. (US)

Clavis Pharma ASA (Norway)

Cyclacel Pharmaceuticals, Inc. (US)

EpiCept Corp. (US)

Genzyme Corporation (US)

Lorus Therapeutics, Inc. (Canada)

Novartis AG (Switzerland)

Onconova Therapeutics, Inc. (US)

Market Segment by Countries, this report splits Europe into several key Countries, with sales (consumption), revenue, market share and growth rate of Acute Myeloid Leukemia (AML) Therapeutic in these countries, from 2011 to 2021 (forecast), like

Germany

France

UK

Russia

Italy

Spain

Benelux

Split by product type, with sales, revenue, price, market share and growth rate of each type, can be divided into

Type I

Type II

Type III

Split by application, this report focuses on sales, market share and growth rate of Acute Myeloid Leukemia (AML) Therapeutic in each application, can be divided into

Application 1

Application 2

Application 3

Contents

Europe Acute Myeloid Leukemia (AML) Therapeutic Market Report 2016

1 ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC OVERVIEW

1.1 Product Overview and Scope of Acute Myeloid Leukemia (AML) Therapeutic

1.2 Classification of Acute Myeloid Leukemia (AML) Therapeutic

1.2.1 Type I

1.2.2 Type II

1.2.3 Type III

1.3 Application of Acute Myeloid Leukemia (AML) Therapeutic

1.3.1 Application

1.3.2 Application

1.3.3 Application

1.4 Acute Myeloid Leukemia (AML) Therapeutic Market by Countries

1.4.1 Germany Status and Prospect (2011-2021)

1.4.2 France Status and Prospect (2011-2021)

1.4.3 UK Status and Prospect (2011-2021)

1.4.4 Russia Status and Prospect (2011-2021)

1.4.5 Italy Status and Prospect (2011-2021)

1.4.6 Spain Status and Prospect (2011-2021)

1.4.7 Benelux Status and Prospect (2011-2021)

1.5 Europe Market Size (Value and Volume) of Acute Myeloid Leukemia (AML) Therapeutic (2011-2021)

1.5.1 Europe Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2021)

1.5.2 Europe Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2021)

2 EUROPE ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC BY MANUFACTURERS, TYPE AND APPLICATION

2.1 Europe Acute Myeloid Leukemia (AML) Therapeutic Market Competition by Manufacturers

2.1.1 Europe Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share of Key Manufacturers (2015 and 2016)

2.1.2 Europe Acute Myeloid Leukemia (AML) Therapeutic Revenue and Share by Manufacturers (2015 and 2016)

2.2 Europe Acute Myeloid Leukemia (AML) Therapeutic (Volume and Value) by Type

2.2.1 Europe Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Type (2011-2016)

2.2.2 Europe Acute Myeloid Leukemia (AML) Therapeutic Revenue and Market Share by Type (2011-2016)

2.3 Europe Acute Myeloid Leukemia (AML) Therapeutic (Volume and Value) by Countries

2.3.1 Europe Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Countries (2011-2016)

2.3.2 Europe Acute Myeloid Leukemia (AML) Therapeutic Revenue and Market Share by Countries (2011-2016)

2.4 Europe Acute Myeloid Leukemia (AML) Therapeutic (Volume) by Application

3 GERMANY ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC (VOLUME, VALUE AND SALES PRICE)

3.1 Germany Acute Myeloid Leukemia (AML) Therapeutic Sales and Value (2011-2016)

3.1.1 Germany Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2016)

3.1.2 Germany Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2016)

3.1.3 Germany Acute Myeloid Leukemia (AML) Therapeutic Sales Price Trend (2011-2016)

3.2 Germany Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Manufacturers

3.3 Germany Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Type

3.4 Germany Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Application

4 FRANCE ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC (VOLUME, VALUE AND SALES PRICE)

4.1 France Acute Myeloid Leukemia (AML) Therapeutic Sales and Value (2011-2016)

4.1.1 France Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2016)

4.1.2 France Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2016)

4.1.4 France Acute Myeloid Leukemia (AML) Therapeutic Sales Price Trend

(2011-2016)

4.2 France Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Manufacturers

4.3 France Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Type

4.4 France Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Application

5 UK ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC (VOLUME, VALUE AND SALES PRICE)

5.1 UK Acute Myeloid Leukemia (AML) Therapeutic Sales and Value (2011-2016)

5.1.1 UK Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2016)

5.1.2 UK Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2016)

5.1.5 UK Acute Myeloid Leukemia (AML) Therapeutic Sales Price Trend (2011-2016)

5.2 UK Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Manufacturers

5.3 UK Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Type

5.4 UK Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Application

6 RUSSIA ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC (VOLUME, VALUE AND SALES PRICE)

6.1 Russia Acute Myeloid Leukemia (AML) Therapeutic Sales and Value (2011-2016)

6.1.1 Russia Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2016)

6.1.2 Russia Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2016)

6.1.6 Russia Acute Myeloid Leukemia (AML) Therapeutic Sales Price Trend (2011-2016)

6.2 Russia Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Manufacturers

6.3 Russia Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Type

6.4 Russia Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Application

7 ITALY ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC (VOLUME, VALUE AND SALES PRICE)

7.1 Italy Acute Myeloid Leukemia (AML) Therapeutic Sales and Value (2011-2016)

7.1.1 Italy Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2016)

7.1.2 Italy Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2016)

7.1.7 Italy Acute Myeloid Leukemia (AML) Therapeutic Sales Price Trend (2011-2016)

7.2 Italy Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Manufacturers

7.3 Italy Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Type

7.4 Italy Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Application

8 SPAIN ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC (VOLUME, VALUE AND SALES PRICE)

8.1 Spain Acute Myeloid Leukemia (AML) Therapeutic Sales and Value (2011-2016)

8.1.1 Spain Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2016)

8.1.2 Spain Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2016)

8.1.8 Spain Acute Myeloid Leukemia (AML) Therapeutic Sales Price Trend (2011-2016)

8.2 Spain Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Manufacturers

8.3 Spain Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Type

8.4 Spain Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Application

9 BENELUX ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC (VOLUME, VALUE AND SALES PRICE)

9.1 Benelux Acute Myeloid Leukemia (AML) Therapeutic Sales and Value (2011-2016)

9.1.1 Benelux Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2016)

9.1.2 Benelux Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate

(2011-2016)

9.1.9 Benelux Acute Myeloid Leukemia (AML) Therapeutic Sales Price Trend

(2011-2016)

9.2 Benelux Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Manufacturers

9.3 Benelux Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Type

9.4 Benelux Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Application

10 EUROPE ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC MANUFACTURERS ANALYSIS

10.1 Ambit Biosciences Inc. (US)

10.1.1 Company Basic Information, Manufacturing Base and Competitors

10.1.2 Acute Myeloid Leukemia (AML) Therapeutic Product Type, Application and Specification

10.1.2.1 Type I

10.1.2.2 Type II

10.1.3 Ambit Biosciences Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)

10.1.4 Main Business/Business Overview

10.2 Aprea AB (Sweden)

10.2.1 Company Basic Information, Manufacturing Base and Competitors

10.2.2 Acute Myeloid Leukemia (AML) Therapeutic Product Type, Application and Specification

10.2.2.1 Type I

10.2.2.2 Type II

10.2.3 Aprea AB (Sweden) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)

10.2.4 Main Business/Business Overview

10.3 Astellas Pharma Inc. (Japan)

10.3.1 Company Basic Information, Manufacturing Base and Competitors

10.3.2 Acute Myeloid Leukemia (AML) Therapeutic Product Type, Application and Specification

10.3.2.1 Type I

10.3.2.2 Type II

10.3.3 Astellas Pharma Inc. (Japan) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)

- 10.3.4 Main Business/Business Overview
- 10.4 Astex Pharmaceuticals, Inc. (US)
 - 10.4.1 Company Basic Information, Manufacturing Base and Competitors
 - 10.4.2 Acute Myeloid Leukemia (AML) Therapeutic Product Type, Application and Specification
 - 10.4.2.1 Type I
 - 10.4.2.2 Type II
 - 10.4.3 Astex Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
 - 10.4.4 Main Business/Business Overview
- 10.5 Bio-Path Holdings, Inc. (US)
 - 10.5.1 Company Basic Information, Manufacturing Base and Competitors
 - 10.5.2 Acute Myeloid Leukemia (AML) Therapeutic Product Type, Application and Specification
 - 10.5.2.1 Type I
 - 10.5.2.2 Type II
 - 10.5.3 Bio-Path Holdings, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
 - 10.5.4 Main Business/Business Overview
- 10.6 BioSante Pharmaceuticals, Inc. (US)
 - 10.6.1 Company Basic Information, Manufacturing Base and Competitors
 - 10.6.2 Acute Myeloid Leukemia (AML) Therapeutic Product Type, Application and Specification
 - 10.6.2.1 Type I
 - 10.6.2.2 Type II
 - 10.6.3 BioSante Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
 - 10.6.4 Main Business/Business Overview
- 10.7 Celator Pharmaceuticals, Inc. (US)
 - 10.7.1 Company Basic Information, Manufacturing Base and Competitors
 - 10.7.2 Acute Myeloid Leukemia (AML) Therapeutic Product Type, Application and Specification
 - 10.7.2.1 Type I
 - 10.7.2.2 Type II
 - 10.7.3 Celator Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
 - 10.7.4 Main Business/Business Overview
- 10.8 Celgene Corp. (US)
 - 10.8.1 Company Basic Information, Manufacturing Base and Competitors

- 10.8.2 Acute Myeloid Leukemia (AML) Therapeutic Product Type, Application and Specification
 - 10.8.2.1 Type I
 - 10.8.2.2 Type II
- 10.8.3 Celgene Corp. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
- 10.8.4 Main Business/Business Overview
- 10.9 Clavis Pharma ASA (Norway)
 - 10.9.1 Company Basic Information, Manufacturing Base and Competitors
 - 10.9.2 Acute Myeloid Leukemia (AML) Therapeutic Product Type, Application and Specification
 - 10.9.2.1 Type I
 - 10.9.2.2 Type II
 - 10.9.3 Clavis Pharma ASA (Norway) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
 - 10.9.4 Main Business/Business Overview
- 10.10 Cyclacel Pharmaceuticals, Inc. (US)
 - 10.10.1 Company Basic Information, Manufacturing Base and Competitors
 - 10.10.2 Acute Myeloid Leukemia (AML) Therapeutic Product Type, Application and Specification
 - 10.10.2.1 Type I
 - 10.10.2.2 Type II
 - 10.10.3 Cyclacel Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
 - 10.10.4 Main Business/Business Overview
- 10.11 EpiCept Corp. (US)
- 10.12 Genzyme Corporation (US)
- 10.13 Lorus Therapeutics, Inc. (Canada)
- 10.14 Novartis AG (Switzerland)
- 10.15 Onconova Therapeutics, Inc. (US)

11 ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC MANUFACTURING COST ANALYSIS

- 11.1 Acute Myeloid Leukemia (AML) Therapeutic Key Raw Materials Analysis
 - 11.1.1 Key Raw Materials
 - 11.1.2 Price Trend of Key Raw Materials
 - 11.1.3 Key Suppliers of Raw Materials
 - 11.1.4 Market Concentration Rate of Raw Materials

11.2 Proportion of Manufacturing Cost Structure

11.2.1 Raw Materials

11.2.2 Labor Cost

11.2.3 Manufacturing Expenses

11.3 Manufacturing Process Analysis of Acute Myeloid Leukemia (AML) Therapeutic

12 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

12.1 Acute Myeloid Leukemia (AML) Therapeutic Industrial Chain Analysis

12.2 Upstream Raw Materials Sourcing

12.3 Raw Materials Sources of Acute Myeloid Leukemia (AML) Therapeutic Major Manufacturers in 2015

12.4 Downstream Buyers

13 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

13.1 Marketing Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Development Trend

13.2 Market Positioning

13.2.1 Pricing Strategy

13.2.2 Brand Strategy

13.2.3 Target Client

13.3 Distributors/Traders List

14 EUROPE ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC MARKET FORECAST (2016-2021)

14.1 Germany Acute Myeloid Leukemia (AML) Therapeutic Sales Forecast (2016-2021)

14.2 France Acute Myeloid Leukemia (AML) Therapeutic Sales Forecast (2016-2021)

14.3 UK Acute Myeloid Leukemia (AML) Therapeutic Sales Forecast (2016-2021)

14.4 Russia Acute Myeloid Leukemia (AML) Therapeutic Sales Forecast (2016-2021)

14.5 Italy Acute Myeloid Leukemia (AML) Therapeutic Sales Forecast (2016-2021)

14.6 Spain Acute Myeloid Leukemia (AML) Therapeutic Sales Forecast (2016-2021)

14.7 Benelux Acute Myeloid Leukemia (AML) Therapeutic Sales Forecast (2016-2021)

14.8 Europe Acute Myeloid Leukemia (AML) Therapeutic Sales Forecast by Type (2016-2021)

14.9 Europe Acute Myeloid Leukemia (AML) Therapeutic Sales Forecast by Application

(2016-2021)

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

Author List

Disclosure Section

Research Methodology

Data Source

Disclaimer

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Acute Myeloid Leukemia (AML) Therapeutic

Table Classification of Acute Myeloid Leukemia (AML) Therapeutic

Figure Europe Sales Market Share of Acute Myeloid Leukemia (AML) Therapeutic by Type in 2015

Figure Type I Picture

Figure Type II Picture

Table Application of Acute Myeloid Leukemia (AML) Therapeutic

Figure Europe Sales Market Share of Acute Myeloid Leukemia (AML) Therapeutic by Application in 2015

Figure Application 1 Examples

Figure Application 2 Examples

Figure Germany Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2021)

Figure France Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2021)

Figure UK Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2021)

Figure Russia Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2021)

Figure Italy Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2021)

Figure Spain Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2021)

Figure Benelux Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2021)

Figure Europe Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2021)

Figure Europe Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2021)

Table Europe Acute Myeloid Leukemia (AML) Therapeutic Sales of Key Manufacturers (2015 and 2016)

Table Europe Acute Myeloid Leukemia (AML) Therapeutic Sales Share by Manufacturers (2015 and 2016)

Figure 2015 Acute Myeloid Leukemia (AML) Therapeutic Sales Share by Manufacturers

Figure 2016 Acute Myeloid Leukemia (AML) Therapeutic Sales Share by Manufacturers

Table Europe Acute Myeloid Leukemia (AML) Therapeutic Revenue by Manufacturers (2015 and 2016)

Table Europe Acute Myeloid Leukemia (AML) Therapeutic Revenue Share by Manufacturers (2015 and 2016)

Table 2015 Europe Acute Myeloid Leukemia (AML) Therapeutic Revenue Share by Manufacturers

Table 2016 Europe Acute Myeloid Leukemia (AML) Therapeutic Revenue Share by Manufacturers

Table Europe Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Type (2011-2016)

Table Europe Acute Myeloid Leukemia (AML) Therapeutic Sales Share by Type (2011-2016)

Figure Sales Market Share of Acute Myeloid Leukemia (AML) Therapeutic by Type (2011-2016)

Figure Europe Acute Myeloid Leukemia (AML) Therapeutic Sales Growth Rate by Type (2011-2016)

Table Europe Acute Myeloid Leukemia (AML) Therapeutic Revenue and Market Share by Type (2011-2016)

Table Europe Acute Myeloid Leukemia (AML) Therapeutic Revenue Share by Type (2011-2016)

Figure Revenue Market Share of Acute Myeloid Leukemia (AML) Therapeutic by Type (2011-2016)

Figure Europe Acute Myeloid Leukemia (AML) Therapeutic Revenue Growth Rate by Type (2011-2016)

Table Europe Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Countries (2011-2016)

Table Europe Acute Myeloid Leukemia (AML) Therapeutic Sales Share by Countries (2011-2016)

Figure Sales Market Share of Acute Myeloid Leukemia (AML) Therapeutic by Countries (2011-2016)

Table Europe Acute Myeloid Leukemia (AML) Therapeutic Revenue and Market Share by Countries (2011-2016)

Table Europe Acute Myeloid Leukemia (AML) Therapeutic Revenue Share by Countries (2011-2016)

Figure Revenue Market Share of Acute Myeloid Leukemia (AML) Therapeutic by Countries (2011-2016)

Table Europe Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Application (2011-2016)

Table Europe Acute Myeloid Leukemia (AML) Therapeutic Sales Share by Application

(2011-2016)

Figure Sales Market Share of Acute Myeloid Leukemia (AML) Therapeutic by Application (2011-2016)

Figure Germany Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2016)

Figure Germany Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2016)

Figure Germany Acute Myeloid Leukemia (AML) Therapeutic Sales Price Trend (2011-2016)

Table Germany Acute Myeloid Leukemia (AML) Therapeutic Sales by Manufacturers (2015 and 2016)

Table Germany Acute Myeloid Leukemia (AML) Therapeutic Market Share by Manufacturers (2015 and 2016)

Table Germany Acute Myeloid Leukemia (AML) Therapeutic Sales by Type (2015 and 2016)

Table Germany Acute Myeloid Leukemia (AML) Therapeutic Market Share by Type (2015 and 2016)

Table Germany Acute Myeloid Leukemia (AML) Therapeutic Sales by Application (2015 and 2016)

Table Germany Acute Myeloid Leukemia (AML) Therapeutic Market Share by Application (2015 and 2016)

Figure France Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2016)

Figure France Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2016)

Figure France Acute Myeloid Leukemia (AML) Therapeutic Sales Price Trend (2011-2016)

Table France Acute Myeloid Leukemia (AML) Therapeutic Sales by Manufacturers (2015 and 2016)

Table France Acute Myeloid Leukemia (AML) Therapeutic Market Share by Manufacturers (2015 and 2016)

Table France Acute Myeloid Leukemia (AML) Therapeutic Sales by Type (2015 and 2016)

Table France Acute Myeloid Leukemia (AML) Therapeutic Market Share by Type (2015 and 2016)

Table France Acute Myeloid Leukemia (AML) Therapeutic Sales by Application (2015 and 2016)

Table France Acute Myeloid Leukemia (AML) Therapeutic Market Share by Application (2015 and 2016)

Figure UK Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2016)

Figure UK Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2016)

Figure UK Acute Myeloid Leukemia (AML) Therapeutic Sales Price Trend (2011-2016)

Table UK Acute Myeloid Leukemia (AML) Therapeutic Sales by Manufacturers (2015 and 2016)

Table UK Acute Myeloid Leukemia (AML) Therapeutic Market Share by Manufacturers (2015 and 2016)

Table UK Acute Myeloid Leukemia (AML) Therapeutic Sales by Type (2015 and 2016)

Table UK Acute Myeloid Leukemia (AML) Therapeutic Market Share by Type (2015 and 2016)

Table UK Acute Myeloid Leukemia (AML) Therapeutic Sales by Application (2015 and 2016)

Table UK Acute Myeloid Leukemia (AML) Therapeutic Market Share by Application (2015 and 2016)

Figure Russia Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2016)

Figure Russia Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2016)

Figure Russia Acute Myeloid Leukemia (AML) Therapeutic Sales Price Trend (2011-2016)

Table Russia Acute Myeloid Leukemia (AML) Therapeutic Sales by Manufacturers (2015 and 2016)

Table Russia Acute Myeloid Leukemia (AML) Therapeutic Market Share by Manufacturers (2015 and 2016)

Table Russia Acute Myeloid Leukemia (AML) Therapeutic Sales by Type (2015 and 2016)

Table Russia Acute Myeloid Leukemia (AML) Therapeutic Market Share by Type (2015 and 2016)

Table Russia Acute Myeloid Leukemia (AML) Therapeutic Sales by Application (2015 and 2016)

Table Russia Acute Myeloid Leukemia (AML) Therapeutic Market Share by Application (2015 and 2016)

Figure Italy Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2016)

Figure Italy Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2016)

Figure Italy Acute Myeloid Leukemia (AML) Therapeutic Sales Price Trend (2011-2016)

Table Italy Acute Myeloid Leukemia (AML) Therapeutic Sales by Manufacturers (2015 and 2016)

Table Italy Acute Myeloid Leukemia (AML) Therapeutic Market Share by Manufacturers (2015 and 2016)

Table Italy Acute Myeloid Leukemia (AML) Therapeutic Sales by Type (2015 and 2016)

Table Italy Acute Myeloid Leukemia (AML) Therapeutic Market Share by Type (2015 and 2016)

Table Italy Acute Myeloid Leukemia (AML) Therapeutic Sales by Application (2015 and 2016)

Table Italy Acute Myeloid Leukemia (AML) Therapeutic Market Share by Application (2015 and 2016)

Figure Spain Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2016)

Figure Spain Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2016)

Figure Spain Acute Myeloid Leukemia (AML) Therapeutic Sales Price Trend (2011-2016)

Table Spain Acute Myeloid Leukemia (AML) Therapeutic Sales by Manufacturers (2015 and 2016)

Table Spain Acute Myeloid Leukemia (AML) Therapeutic Market Share by Manufacturers (2015 and 2016)

Table Spain Acute Myeloid Leukemia (AML) Therapeutic Sales by Type (2015 and 2016)

Table Spain Acute Myeloid Leukemia (AML) Therapeutic Market Share by Type (2015 and 2016)

Table Spain Acute Myeloid Leukemia (AML) Therapeutic Sales by Application (2015 and 2016)

Table Spain Acute Myeloid Leukemia (AML) Therapeutic Market Share by Application (2015 and 2016)

Figure Benelux Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2016)

Figure Benelux Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2016)

Figure Benelux Acute Myeloid Leukemia (AML) Therapeutic Sales Price Trend (2011-2016)

Table Benelux Acute Myeloid Leukemia (AML) Therapeutic Sales by Manufacturers (2015 and 2016)

Table Benelux Acute Myeloid Leukemia (AML) Therapeutic Market Share by Manufacturers (2015 and 2016)

Table Benelux Acute Myeloid Leukemia (AML) Therapeutic Sales by Type (2015 and 2016)

Table Benelux Acute Myeloid Leukemia (AML) Therapeutic Market Share by Type (2015 and 2016)

Table Benelux Acute Myeloid Leukemia (AML) Therapeutic Sales by Application (2015 and 2016)

Table Benelux Acute Myeloid Leukemia (AML) Therapeutic Market Share by Application (2015 and 2016)

Table Acute Myeloid Leukemia (AML) Therapeutic Basic Information List

Table Ambit Biosciences Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)

Figure Ambit Biosciences Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)

Table Aprea AB (Sweden) Basic Information List

Table Aprea AB (Sweden) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)

Table Aprea AB (Sweden) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)

Table Astellas Pharma Inc. (Japan) Basic Information List

Table Astellas Pharma Inc. (Japan) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)

Table Astellas Pharma Inc. (Japan) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)

Table Astex Pharmaceuticals, Inc. (US) Basic Information List

Table Astex Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)

Table Astex Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)

Table Bio-Path Holdings, Inc. (US) Basic Information List

Table Bio-Path Holdings, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)

Table Bio-Path Holdings, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)

Table BioSante Pharmaceuticals, Inc. (US) Basic Information List

Table BioSante Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)

Table BioSante Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)

Table Celator Pharmaceuticals, Inc. (US) Basic Information List

- Table Celator Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
- Table Celator Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)
- Table Celgene Corp. (US) Basic Information List
- Table Celgene Corp. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
- Table Celgene Corp. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)
- Table Clavis Pharma ASA (Norway) Basic Information List
- Table Clavis Pharma ASA (Norway) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
- Table Clavis Pharma ASA (Norway) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)
- Table Cyclacel Pharmaceuticals, Inc. (US) Basic Information List
- Table Cyclacel Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
- Table Cyclacel Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)
- Table EpiCept Corp. (US) Basic Information List
- Table EpiCept Corp. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
- Table EpiCept Corp. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)
- Table Genzyme Corporation (US) Basic Information List
- Table Genzyme Corporation (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
- Table Genzyme Corporation (US) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)
- Table Lorus Therapeutics, Inc. (Canada) Basic Information List
- Table Lorus Therapeutics, Inc. (Canada) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
- Table Lorus Therapeutics, Inc. (Canada) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)
- Table Novartis AG (Switzerland) Basic Information List
- Table Novartis AG (Switzerland) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
- Table Novartis AG (Switzerland) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)

Table Onconova Therapeutics, Inc. (US) Basic Information List

Table Onconova Therapeutics, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)

Table Onconova Therapeutics, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Acute Myeloid Leukemia (AML) Therapeutic

Figure Manufacturing Process Analysis of Acute Myeloid Leukemia (AML) Therapeutic

Figure Acute Myeloid Leukemia (AML) Therapeutic Industrial Chain Analysis

Table Raw Materials Sources of Acute Myeloid Leukemia (AML) Therapeutic Major Manufacturers in 2015

Table Major Buyers of Acute Myeloid Leukemia (AML) Therapeutic

Table Distributors/Traders List

Figure Germany Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate Forecast (2016-2021)

Figure Germany Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate Forecast (2016-2021)

Figure France Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate Forecast (2016-2021)

Figure France Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate Forecast (2016-2021)

Figure UK Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate Forecast (2016-2021)

Figure UK Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate Forecast (2016-2021)

Figure Russia Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate Forecast (2016-2021)

Figure Russia Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate Forecast (2016-2021)

Figure Italy Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate Forecast (2016-2021)

Figure Italy Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate Forecast (2016-2021)

Figure Spain Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate Forecast (2016-2021)

Figure Spain Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate Forecast (2016-2021)

Figure Benelux Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate Forecast (2016-2021)

Figure Benelux Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate Forecast (2016-2021)

Table Europe Acute Myeloid Leukemia (AML) Therapeutic Sales Forecast by Type (2016-2021)

Table Europe Acute Myeloid Leukemia (AML) Therapeutic Sales Forecast by Application (2016-2021)

I would like to order

Product name: Europe Acute Myeloid Leukemia (AML) Therapeutic Market Report 2016

Product link: <https://marketpublishers.com/r/E99A29625B1EN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E99A29625B1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970